Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
Public ClinicalTrials.gov record NCT01265576. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Study identification
- NCT ID
- NCT01265576
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- Feb 2014 (Actual)
- Completion
- Apr 2016 (Estimated)
- Last update posted
- Dec 9, 2015
2010 – 2016
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Vicus Clinical Site | Berkeley | California | 94704 | — |
| Vicus Clinical Site | Atlanta | Georgia | 30318 | — |
| Vicus Clinical Site | New Brunswick | New Jersey | — | — |
| Vicus Clinical Site | Newark | New Jersey | 07103 | — |
| Vicus Clinical Site | Paterson | New Jersey | 07503 | — |
| Vicus Clinical Site | Buffalo | New York | 14263 | — |
| Vicus Clinical Site | New York | New York | 10016 | — |
| Vicus Clinical Site | Philadelphia | Pennsylvania | — | — |
| Vicus Clinical Site | Houston | Texas | 77024 | — |
| Vicus Clinical Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01265576, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01265576 live on ClinicalTrials.gov.